BioSpace News Archive

- 40% increase in muscle size compared to control mice - 25% increase in muscle force, approaching levels seen in normal mice

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fiscal year ending September 30, 2023.

Carina Biotech Pty Ltd (Carina), a cell therapy immuno-oncology company, today announced that a poster presentation with preclinical data supporting the effectiveness of its LGR5-targeted CAR-T platform in ovarian cancer cell models will be presented at the 35th Annual Lorne Cancer Conference.

American Journal of Hematology recently published the phase 2 study result of BTK inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma patients.

Viridian Therapeutics, Inc. today announced that the Company has appointed Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today February 6, 2023.

Singular Genomics Systems, Inc. today announced the launch of its Max Read™ Kits for single cell applications on the company’s G4 Sequencing Platform at the Advances in Genome Biology and Technology (AGBT) 23rd General Meeting, taking place February 6–9, 2023, in Hollywood, Florida.

TransMed7, LLC announced today that the “First in Human” series of clinical cases using commercial production Concorde US devices.

NeoGenomics, Inc. announced today that it plans to release its fourth quarter and full year 2022, financial results on Thursday, February 23, 2023.

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.

Heart Test Laboratories, Inc. today announced it has been granted a patent in Israel (Patent No. 10-2490960) from the Israel Patent Office.